The U.S. Food and Drug Administration should avoid using words like "breakthrough" and "promising" to describe new drugs when making announcements aimed at the public, some researchers argue.
The U.S. Food and Drug Administration should avoid using words like "breakthrough" and "promising" to describe new drugs when making announcements aimed at the public, some researchers argue.